Eyegate Pharmaceuticals (NASDAQ: EYEG) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate Ocular Bandage Gel (“OBG”) is being evaluated in a pilot study for corneal re-epithelialization following photorefractive keratectomy (“PRK”) surgery. EyeGate OBG is classified as a Class 2 medical device, and Eyegate intends to pursue U.S. regulatory clearance via the FDA’s De Novo 510(k) pathway. The company’s second product, EGP-437, integrates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through a proprietary innovative drug delivery system, the EyeGate II Delivery System. EGP-437 is currently in late-stage clinical trials evaluating the product in treatment of both anterior uveitis and pain and inflammation following cataract surgery. For more information, visit the company’s website at www.eyegatepharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
